Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
-
- Roy Rabbie
- Experimental Cancer Genetics The Wellcome Sanger Institute Hinxton UK
-
- Peter Ferguson
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital Sydney Australia
-
- Christian Molina‐Aguilar
- Laboratorio Internacional de Investigación sobre el Genoma Humano Universidad Nacional Autónoma de México Santiago de Querétaro Mexico
-
- David J Adams
- Experimental Cancer Genetics The Wellcome Sanger Institute Hinxton UK
-
- Carla D Robles‐Espinoza
- Experimental Cancer Genetics The Wellcome Sanger Institute Hinxton UK
抄録
<jats:title>Abstract</jats:title><jats:p>Melanoma is characterised by its ability to metastasise at early stages of tumour development. Current clinico‐pathologic staging based on the American Joint Committee on Cancer criteria is used to guide surveillance and management in early‐stage disease, but its ability to predict clinical outcome has limitations. Herein we review the genomics of melanoma subtypes including cutaneous, acral, uveal and mucosal, with a focus on the prognostic and predictive significance of key molecular aberrations. © 2018 The Authors. <jats:italic>The Journal of Pathology</jats:italic> published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</jats:p>
収録刊行物
-
- The Journal of Pathology
-
The Journal of Pathology 247 (5), 539-551, 2019-02-15
Wiley